Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Multi-center, Placebo-Controlled Trial of Sorafenib (BAY43-9006) in Patients With Relapsed or Refractory Advanced Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC) After 2 or 3 Previous Treatment Regimens for Advanced Disease

NCT00863746 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT00863746
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00863746 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Multi-center, Placebo-Controlled Trial of Sorafenib (BAY43-9006) in Patients With Relapsed or Refractory Advanced Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC) After 2 or 3 Previous Treatment Regimens for Advanced Disease
Lead sponsor
Bayer
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2009
Completion date
April 30, 2013
Enrollment
703 (actual)
Sites
182

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small-cell lung